| 赵小辉,卢双动,陈杰,徐阳,王会哲.重组人尿激酶原与阿替普酶溶栓治疗急性ST段抬高型心肌梗死的作用评价.[J].中南医学科学杂志.,2021,(1):72-77. |
| 重组人尿激酶原与阿替普酶溶栓治疗急性ST段抬高型心肌梗死的作用评价 |
| The evaluation of recombinant human prourokinase versus alteplase in the treatment of acute ST-segment elevation myocardial infarction |
| |
| DOI：10.15972/j.cnki.43-1509/r.2021.01.014 |
| 中文关键词: 重组人尿激酶原 阿替普酶 急性心肌梗死 冠状动脉造影 溶栓 |
| 英文关键词:recombinant human prourokinase alteplase acute myocardial infarction coronary angiography thrombolysis |
| 基金项目: |
|
| 摘要点击次数: 513 |
| 全文下载次数: 418 |
| 中文摘要: |
| 目的探究重组人尿激酶原与阿替普酶溶栓治疗急性ST段抬高型心肌梗死(STEMI)的疗效及临床安全性。方法制定入组标准,选取STEMI患者100例,随机均分为尿激酶原组(50例)和阿替普酶组(50例)。分析两组冠状动脉造影结果,比较患者接受静脉溶栓后病变血管再通情况,观察并记录各项临床事件。结果与阿替普酶组比较,尿激酶原组患者在接受静脉溶栓后24 h内冠状动脉通畅率更高；尿激酶原组和阿替普酶组患者溶栓后24 h内冠状动脉造影发现,溶栓后存在补救性PCI指征(TIMI 0～1级)患者数量的差异有显著性(10.0%比38.0%,加权前P＝0.021,加权后P＝0.025)；TIMI 0级、TIMI 1级、TIMI 4级的患者数量两组差异有显著性,TIMI 3级的患者数量两组间差异无显著性。两组在临床终点事件、住院期间不良事件发生率以及随访过程中不良事件发生率方面的差异无统计学意义。结论与阿替普酶相比,重组人尿激酶原在急性心肌梗死的治疗方面具有更好的疗效和安全性,值得临床推广应用。 |
| 英文摘要: |
| To investigate the efficacy and safety of recombinant human prourokinase versus alteplase in the treatment of acute ST-segment elevation myocardial infarction. Methods100 patients were selected as the study subjects. All patients were divided randomly into recombinant human prourokinase group (50 cases), alteplase group (50 cases). Coronary angiography was used to compare the recanalization of diseased vessels after intravenous thrombolysis in the two groups, various clinical events were observed and recorded. ResultsCompared with the alteplase intravenous thrombolysis group, the patients in the recombinant human prourokinase group had higher coronary artery patency within 24 hours after intravenous thrombolysis; for the recombinant human prourokinase group and the alteplase group after thrombolysis, coronary angiography within 24 hours showed there was a significant difference in the number of patients with salvage PCI indications (TIMI 0~1) after thrombolysis (10.0% vs. 38.0%, P＝0.021 before weighting, P＝0.025 after weighting). There was a significant difference in the number of TIMI 0, TIMI 1, and TIMI 4 patients between the two groups, and there was no significant difference in the number of TIMI 3 patients between the two groups. ConclusionCompared with intravenous injection of alteplase, recombinant human prourokinase has better efficacy and safety in the treatment of acute myocardial infarction, which is worthy of clinical application. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|